Over the past two decades randomized controlled trials of combination treatments for Pulmonary Arterial Hypertension (PAH) have demonstrated improvements of clinical status but only modest reductions in mean pulmonary arterial pressure (mPAP). Recent experiences with upfront combination treatments including parenteral prostacyclins have shown more substantial mPAP reductions, and have provided grounds for reconsiderations of treatment.
Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension. determinants and clinical impact / Badagliacca, Roberto; Vizza, Carmine Dario; Lang, Irene; Sadushi-Kolici, Roela; Papa, Silvia; Manzi, Giovanna; Filomena, Domenico; Ogawa, Aiko; Shimokawahara, Hiroto; Matsubara, Hiromi. - In: VASCULAR PHARMACOLOGY. - ISSN 1879-3649. - 146:(2022). [10.1016/j.vph.2022.107099]
Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension. determinants and clinical impact
Badagliacca, Roberto
;Vizza, Carmine Dario;Papa, Silvia;Manzi, Giovanna;Filomena, Domenico;
2022
Abstract
Over the past two decades randomized controlled trials of combination treatments for Pulmonary Arterial Hypertension (PAH) have demonstrated improvements of clinical status but only modest reductions in mean pulmonary arterial pressure (mPAP). Recent experiences with upfront combination treatments including parenteral prostacyclins have shown more substantial mPAP reductions, and have provided grounds for reconsiderations of treatment.File | Dimensione | Formato | |
---|---|---|---|
Badagliacca_Pulmonary_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
2.88 MB
Formato
Adobe PDF
|
2.88 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.